PE20080892A1 - N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-iliden)metil)benzamida - Google Patents

N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-iliden)metil)benzamida

Info

Publication number
PE20080892A1
PE20080892A1 PE2007001423A PE2007001423A PE20080892A1 PE 20080892 A1 PE20080892 A1 PE 20080892A1 PE 2007001423 A PE2007001423 A PE 2007001423A PE 2007001423 A PE2007001423 A PE 2007001423A PE 20080892 A1 PE20080892 A1 PE 20080892A1
Authority
PE
Peru
Prior art keywords
methyl
iliden
quinolin
benzamide
piperidin
Prior art date
Application number
PE2007001423A
Other languages
English (en)
Inventor
Khanh Bui
Cathy Dantzman
Glen Ernst
Valerie Hoesch
Thomas Hudzik
Megan Murphy King
Jie Liu
Jingbo Yan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20080892A1 publication Critical patent/PE20080892A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A UN COMPUESTO QUE ES N-(2-HIDROXIETIL)-N-METIL-4-(QUINOLIN-8-IL(1-(TIAZOL-4-ILMETIL)PIPERIDIN-4-ILIDEN)METIL)BENZAMIDA Y COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHO COMPUESTO Y ADEMAS VEHICULOS INERTES COMO CARBONATO O ESTEARATO DE MAGNESIO, TALCO, LACTOSA, CARBOXIMETILCELULOSA, CERAS DE BAJO PUNTO DE FUSION, AGUA, PROPILENGLICOL, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION QUE COMPRENDE: A) HACER REACCIONAR 4-(BROMO-{4-[(2-HIDROXI-ETIL)-METIL-CARBAMOIL]-FENIL}-METILEN)-PIPERIDINA PROTEGIDA CON ACIDO 8-QUINOLINBORICO PARA OBTENER N-(2-HIDROXIETIL)-N-METIL-4-(PIPERIDIN-4-ILIDEN-QUINOLIN-8-IL-METIL)BENZAMIDA PROTEGIDA, EL CUAL ES DESPROTEGIDO POSTERIORMENTE; B) HACER REACCIONAR N-(2-HIDROXIETIL)-N-METIL-4-(PIPERIDIN-4-ILIDEN-QUINOLIN-8-IL-METIL)BENZAMIDA CON TIAZOL-4-CARBALDEHIDO PARA FORMAR N-(2-HIDROXIETIL)-N-METIL-4-(QUINOLIN-8-IL(1-(TIAZOL-4-ILMETIL)PIPERIDIN-4-ILIDEN)METIL)BENZAMIDA. DICHO COMPUESTO ES AGONISTA DEL RECEPTOR OPIODE SIENDO UTIL EN LA TERAPIA DEL DOLOR, ANSIEDAD, DEPRESION, ENFERMEDAD DE PARKINSON
PE2007001423A 2006-10-20 2007-10-19 N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-iliden)metil)benzamida PE20080892A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86232706P 2006-10-20 2006-10-20

Publications (1)

Publication Number Publication Date
PE20080892A1 true PE20080892A1 (es) 2008-09-11

Family

ID=39314285

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007001423A PE20080892A1 (es) 2006-10-20 2007-10-19 N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-iliden)metil)benzamida
PE2012001060A PE20140634A1 (es) 2006-10-20 2012-07-24 N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-iliden)metil)benzamida

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2012001060A PE20140634A1 (es) 2006-10-20 2012-07-24 N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-iliden)metil)benzamida

Country Status (33)

Country Link
US (2) US7659286B2 (es)
EP (1) EP2079735B1 (es)
JP (1) JP4668346B2 (es)
KR (1) KR20090065534A (es)
CN (1) CN101528739B (es)
AR (1) AR063345A1 (es)
AT (1) ATE543818T1 (es)
AU (2) AU2007313515B2 (es)
BR (1) BRPI0717631A2 (es)
CA (1) CA2667041C (es)
CL (1) CL2007003009A1 (es)
CO (1) CO6180450A2 (es)
CY (1) CY1112718T1 (es)
DK (1) DK2079735T3 (es)
ES (1) ES2379519T3 (es)
HK (1) HK1131556A1 (es)
HR (1) HRP20120344T1 (es)
IL (1) IL197876A0 (es)
MX (1) MX2009003974A (es)
MY (1) MY148880A (es)
NO (1) NO20091969L (es)
NZ (1) NZ577060A (es)
PE (2) PE20080892A1 (es)
PL (1) PL2079735T3 (es)
PT (1) PT2079735E (es)
RS (1) RS52260B (es)
RU (1) RU2454414C2 (es)
SA (1) SA07280549B1 (es)
SI (1) SI2079735T1 (es)
TW (1) TW200826939A (es)
UA (1) UA97648C2 (es)
UY (1) UY30652A1 (es)
WO (1) WO2008048171A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007503457A (ja) * 2003-05-16 2007-02-22 アストラゼネカ・アクチエボラーグ ジアリールメチリデンピペリジン誘導体、その製造およびその使用
MY148880A (en) 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression
NZ590041A (en) * 2008-05-20 2012-11-30 Astrazeneca Ab Method of treating anxious major depressive disorder
CN101906078B (zh) * 2009-06-08 2012-02-01 上海威智医药科技有限公司 噻唑衍生物的合成方法
CN102106807B (zh) * 2009-12-29 2013-03-27 上海中西制药有限公司 一种固体制剂的制备方法及所得固体制剂
WO2020061165A1 (en) 2018-09-21 2020-03-26 Garland Industries, Inc. Helical hardbanding

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2898339A (en) * 1957-07-29 1959-08-04 Wm S Merrell Co N-substituted benzhydrol, benzhydryl, and benzhydrylidene piperidine
US4581171A (en) * 1983-07-27 1986-04-08 Janssen Pharmaceutica, N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones useful for treating psychotropic disorders
TW548271B (en) 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
AU2009799A (en) * 1997-12-24 1999-07-19 Ortho-Mcneil Pharmaceutical, Inc. 4-(aryl(piperidin-4-yl)) aminobenzamides which bind to the delta-opioid receptor
US6492375B2 (en) * 1998-06-30 2002-12-10 Neuromed Technologies, Inc. Partially saturated calcium channel blockers
SE9904673D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
JP2003518107A (ja) 1999-12-20 2003-06-03 ニューロメド テクノロジーズ, インコーポレイテッド 部分飽和カルシウムチャネルブロッカー
AU2001241676A1 (en) * 2000-03-03 2001-09-17 Ortho-Mcneil Pharmaceutical, Inc. 3-(diarylmethylene)-8-azabicyclo(3.2.1)octane derivatives
SE0001208D0 (sv) * 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
SE0101768D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab Novel compounds
US20040204404A1 (en) * 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
SE0300105D0 (sv) * 2003-01-16 2003-01-16 Astrazeneca Ab Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
SE0301445D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301444D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301441D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0301442D0 (sv) * 2003-05-16 2003-05-16 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations therof and uses thereof
JP2007503457A (ja) * 2003-05-16 2007-02-22 アストラゼネカ・アクチエボラーグ ジアリールメチリデンピペリジン誘導体、その製造およびその使用
SE0400025D0 (sv) * 2004-01-09 2004-01-09 Astrazeneca Ab Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
WO2005087742A1 (en) 2004-03-08 2005-09-22 Exelixis, Inc. Metabolic kinase modulators and methods of use as pesticides
MY148880A (en) 2006-10-20 2013-06-14 Astrazeneca Ab N-(2-hydroxyethyl)-n-methyl-4-(quinolin-8-yl(1-(thiazol-4-ylmethyl)piperidin-4-ylidene)methyl)benzamide, the process of making it as well as its use for the treatment of pain, anxiety and depression

Also Published As

Publication number Publication date
HRP20120344T1 (hr) 2012-05-31
MX2009003974A (es) 2009-04-27
RS52260B (en) 2012-10-31
PT2079735E (pt) 2012-05-07
JP4668346B2 (ja) 2011-04-13
PE20140634A1 (es) 2014-06-19
ES2379519T3 (es) 2012-04-26
EP2079735A1 (en) 2009-07-22
CY1112718T1 (el) 2016-02-10
AR063345A1 (es) 2009-01-21
ATE543818T1 (de) 2012-02-15
SI2079735T1 (sl) 2012-05-31
AU2007313515B2 (en) 2010-11-25
CA2667041A1 (en) 2008-04-24
US7659286B2 (en) 2010-02-09
RU2009111337A (ru) 2010-11-27
SA07280549B1 (ar) 2010-09-29
JP2010506910A (ja) 2010-03-04
CN101528739A (zh) 2009-09-09
AU2010226996A1 (en) 2010-10-28
NO20091969L (no) 2009-05-20
RU2454414C2 (ru) 2012-06-27
NZ577060A (en) 2011-01-28
EP2079735A4 (en) 2010-12-29
AU2007313515A1 (en) 2008-04-24
BRPI0717631A2 (pt) 2013-10-29
IL197876A0 (en) 2009-12-24
US7977355B2 (en) 2011-07-12
CN101528739B (zh) 2011-11-30
UA97648C2 (ru) 2012-03-12
UY30652A1 (es) 2008-05-31
KR20090065534A (ko) 2009-06-22
DK2079735T3 (da) 2012-05-21
US20080182875A1 (en) 2008-07-31
EP2079735B1 (en) 2012-02-01
CA2667041C (en) 2011-09-06
CL2007003009A1 (es) 2008-06-06
PL2079735T3 (pl) 2012-07-31
WO2008048171A1 (en) 2008-04-24
US20100160374A1 (en) 2010-06-24
MY148880A (en) 2013-06-14
HK1131556A1 (es) 2010-01-29
CO6180450A2 (es) 2010-07-19
TW200826939A (en) 2008-07-01

Similar Documents

Publication Publication Date Title
PE20080892A1 (es) N-(2-hidroxietil)-n-metil-4-(quinolin-8-il(1-(tiazol-4-ilmetil)piperidin-4-iliden)metil)benzamida
NZ594597A (en) Substituted piperidines as ccr3 antagonists
CU23691B7 (es) Derivados de pirazol fusionado y métodos de tratamiento de los desórdenes relacionados con el metabolismo
PE20080186A1 (es) Derivados 4,6-disustituidos de 2-metoxi-6-etilamino-pirimidina como antagonistas del receptor de prostaglandina d2
MX2007005126A (es) Compuesto de indolina y proceso para producir el mismo.
PE20121395A1 (es) Derivados de benzamida sustituidos con actividad sobre los receptores asociados a rastros de aminas
ES2620742T3 (es) Formulaciones de principio activo que contienen 2-tiazol-4il-1H-benzoimidazol (tiabendazol o TBZ) para la fabricación de WPC
BRPI0609636A2 (pt) formulações farmacêuticas
NZ600637A (en) Pyrazole compounds as crth2 antagonists
CL2008003787A1 (es) Compuestos derivados de heteroarilo, antagonistas del receptor de orexina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos del sueno, trastornos psiquiatricos, neurologicos, ansiedad, depresion, esquizofrenia, alzheimer, parkinson, entre otras.
AR063305A1 (es) Hidratos de 2-cloro-5-[3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)-pirimidinil]-4-fluor-n-[[metil(1-metiletil)amino]sulfonil]benzamida
PE20070791A1 (es) Sal de dihidrogeno fosfato del acido 2-(3-{6-[2-(2,4-dicloro-fenil)-etilamino]-2-metoxi-pirimidin-4-il}-fenil)-2-metil-propionico
BRPI0921063B8 (pt) composto, e, composição agonística para receptor de melanocortina
AR068879A1 (es) Compuestos organicos
NZ620635A (en) Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
SMT201300108B (it) Nuove composizioni di 1-Ä2-(2,4-dimetilfenil solfanil)-fenilÜ piperazina
MX2022007105A (es) Formas solidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-am ina de acido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1, 3] dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il) metil)-1h- benzo[d]imidazol-6-carboxilico.
UA92195C2 (ru) Оптически активные карбаматы, способ их получения и их применение в качестве фармацевтических промежуточных соединений
CL2004000695A1 (es) Compuestos derivados de 4-fenil piperidina, composicion farmaceutica, util como modulador del receptor opioides, para tratar sindrome de intestino irritable, adiccion o dependencia de drogas, depresion, ansiedad, esquizofrenia, trastornos de la alime
BR112013018938A8 (pt) composto antifúngico tópico, agente antifúngico para tinha e agente antitinha das unhas.
NZ595823A (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
PE20080133A1 (es) 5-amino-6-bromo-n-{[1-(tetrahidro-2h-piran-4-ilmetil)-4-piperidinil]metil}-3,4-dihidro-2h-cromen-8-carboxamida como activador del receptor 5-ht4
NO20090190L (no) Modulatorer av kjemokin reseptor aktivitet, krystallinske former og fremgangsmate
NZ630612A (en) Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed